The rise of short-course radiation is an example of the evidentiary blind spots that bedevil the treatment of prostate cancer. The newer therapy is more intense than standard radiation and takes much less time — five sessions over two weeks instead of 40 sessions over about two months or 28 sessions over five to six weeks.